MedTrace Logo

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

NCT02837991 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-06-04

No results posted yet for this study

Summary

This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).

Conditions

  • Renal Cell Carcinoma (RCC)
  • Clear-cell Renal Cell Carcinoma
  • Papillary Renal Cell Carcinoma
  • Kidney Neoplasms
  • Metastatic Renal Cell Carcinoma
  • Ovarian Clear Cell Carcinoma

Interventions

DRUG

CDX-014

Sponsors & Collaborators

  • Celldex Therapeutics

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-11-16
Completion
2018-11-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02837991 on ClinicalTrials.gov